Technical Specifications
Compound Name: CJC-1295 noDAC
Quantity: 5mg per vial
Format: Lyophilized peptide powder
Peptide Length: 29 amino acids (modified GRF 1-29 analogue)
Molecular Weight: Approximately 3367.9 g/mol
Purity Standard: ≥98% (HPLC, batch dependent)
Modification: No Drug Affinity Complex (noDAC)
Research Classification: Investigational peptide – laboratory research use only
CJC-1295 noDAC 5mg Canada is supplied as a lyophilized synthetic peptide intended exclusively for laboratory and analytical applications. Each vial contains 5 milligrams of the modified growth hormone–releasing hormone (GHRH) analogue, prepared under controlled handling and quality-verification standards appropriate for research material distribution.
This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada.
Research Overview
CJC-1295 noDAC is a modified analogue of growth hormone–releasing hormone (GHRH), specifically derived from the first 29 amino acids of endogenous GHRH with amino acid substitutions designed to enhance stability in experimental systems. The “noDAC” designation indicates the absence of the Drug Affinity Complex modification found in other CJC-1295 variants.
Research involving CJC-1295 noDAC 5mg Canada typically focuses on pulsatile growth hormone signalling, pituitary receptor activation, and endocrine axis modulation in laboratory settings. In academic literature, modified GRF (1-29) analogues have been studied for their interaction with the GHRH receptor in vitro and in preclinical models.
CJC-1295 noDAC has been investigated in controlled research environments to examine its pharmacokinetics, receptor binding affinity, and growth hormone pulse amplitude. Studies often compare noDAC and DAC-modified versions to evaluate differences in half-life and receptor engagement patterns.
CJC-1295 noDAC 5mg Canada is supplied strictly for research purposes. References to hormonal pathways reflect investigational findings from laboratory and clinical research and do not imply authorized clinical use.
Mechanism Overview
CJC-1295 noDAC functions in laboratory models as an agonist of the growth hormone–releasing hormone receptor (GHRHR), which is located primarily in the anterior pituitary gland. Activation of this receptor stimulates adenylate cyclase activity, increasing intracellular cyclic AMP (cAMP) levels and leading to growth hormone release in experimental systems.
The noDAC version lacks the albumin-binding Drug Affinity Complex modification, resulting in a shorter half-life compared to DAC-modified variants in preclinical studies. This distinction allows researchers to evaluate pulsatile hormone dynamics more closely aligned with endogenous GHRH activity.
Investigations involving CJC-1295 noDAC 5mg Canada typically assess receptor activation profiles, downstream signalling cascades, and hormone release patterns in controlled laboratory environments. Mechanistic descriptions are based on preclinical and investigational data and are presented for educational purposes only.
Clinical Development Context
Modified GRF analogues, including CJC-1295 variants, have been studied in early-phase clinical research exploring endocrine signalling and growth hormone dynamics. Published literature describes pharmacokinetic and pharmacodynamic analyses conducted under regulated research protocols.
Despite these investigations, CJC-1295 noDAC 5mg, supplied in research-grade format, is categorized strictly as an investigational laboratory compound. It is distinct from any approved pharmaceutical product and is not authorized for prescription use in Canada.
Ongoing scientific interest in GHRH analogues persists among academic and research institutions that study endocrine physiology.
Regulatory Status in Canada
CJC-1295 noDAC is not approved by Health Canada as a therapeutic drug, natural health product, or over-the-counter medication when supplied in research format.
CJC-1295 noDAC 5mg Canada is classified as an investigational research peptide and is supplied exclusively for laboratory and analytical use. It is not intended for human or veterinary administration.
Handling, storage, and study of CJC-1295 noDAC 5mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical and biological research materials. Research institutions are responsible for maintaining regulatory compliance.
Molecular and Structural Notes
CJC-1295 noDAC is based on the 29-amino-acid sequence of endogenous GHRH with specific amino acid substitutions designed to improve enzymatic stability. These modifications reduce susceptibility to dipeptidyl peptidase-IV (DPP-IV) degradation in experimental systems.
The absence of the Drug Affinity Complex modification differentiates this version from DAC-modified CJC-1295, which contains a reactive moiety that enables covalent albumin binding and extended half-life.
CJC-1295 noDAC 5mg Canada is typically characterized using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity before distribution.
The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.
Frequently Asked Questions
What is CJC-1295 noDAC 5mg Canada studied for in research?
CJC-1295 noDAC 5mg Canada is studied in laboratory settings to investigate GHRH receptor activation and growth hormone signalling dynamics.
Is CJC-1295 noDAC approved for medical use in Canada?
No. Health Canada does not authorize it for therapeutic or consumer use in research-grade form.
What does “noDAC” mean?
It indicates the absence of the Drug Affinity Complex modification, resulting in different pharmacokinetic properties in experimental models than those of DAC-modified versions.
Does CJC-1295 noDAC 5mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide compound.
Can CJC-1295 noDAC 5mg Canada be used outside research facilities?
No. It is supplied strictly for controlled laboratory and analytical research purposes.
Educational Disclaimer
CJC-1295 noDAC 5mg Canada is an investigational research peptide supplied solely for laboratory and analytical use. Health Canada does not approve it as a medication, therapeutic agent, or consumer product.
Information provided on this page is educational in nature and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.
Study and handling of CJC-1295 noDAC 5mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.
Reviews
There are no reviews yet